Xencor (NASDAQ:XNCR - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report released on Saturday, Wall Street Zen reports.
Other research analysts have also recently issued reports about the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Xencor in a report on Monday, September 21st. Barclays set a $45.00 price objective on Xencor and gave the company an "overweight" rating in a research note on Monday, October 26th. Cantor Fitzgerald assumed coverage on Xencor in a report on Thursday. They set an "overweight" rating and a $70.00 price objective on the stock. Raymond James Financial increased their price target on shares of Xencor from $40.00 to $46.00 and gave the company a "strong-buy" rating in a research note on Tuesday, September 1st. Finally, Wells Fargo & Company lifted their target price on shares of Xencor from $30.00 to $44.00 and gave the stock an "overweight" rating in a research note on Tuesday, October 27th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $42.22.
Read Our Latest Research Report on XNCR
Xencor Stock Up 5.0%
Shares of XNCR opened at $35.75 on Friday. The firm's 50 day simple moving average is $26.17 and its 200 day simple moving average is $17.46. Xencor has a 1-year low of $10.38 and a 1-year high of $36.50.
Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The biopharmaceutical company reported $0.50 EPS for the quarter, beating the consensus estimate of ($0.33) by $0.83. The firm had revenue of $116.52 million during the quarter, compared to the consensus estimate of $63.00 million. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. Xencor's revenue for the quarter was up 453.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.08) EPS. On average, sell-side analysts anticipate that Xencor will post -3.14 EPS for the current year.
Hedge Funds Weigh In On Xencor
A number of institutional investors and hedge funds have recently modified their holdings of the company. Johnson & Johnson acquired a new stake in shares of Xencor in the second quarter valued at $12,043,798. Hsbc Holdings PLC boosted its position in Xencor by 114.2% during the 2nd quarter. Hsbc Holdings PLC now owns 125,482 shares of the biopharmaceutical company's stock valued at $2,083,000 after acquiring an additional 66,903 shares in the last quarter. Man Group plc purchased a new position in shares of Xencor in the second quarter valued at about $940,000. Primecap Management Co. CA bought a new stake in Xencor during the 2nd quarter valued at $163,919,000. Finally, Seven Fleet Capital Management LP purchased a new position in Xencor during the second quarter worth approximately $7,828,524,000.
Xencor Company Profile
(
Get Free Report)
Xencor, Inc is a clinical-stage biopharmaceutical company headquartered in Monrovia, California. Founded in 1997, the company develops engineered antibodies and other biologic medicines for the treatment of cancer, autoimmune disorders and other serious diseases.
Xencor's research is centered on its XmAb technology platform, which is designed to modify antibodies to improve their therapeutic properties or create new antibody-based mechanisms. The platform supports the development of bispecific antibodies, immune-cell engagers and antibodies with extended activity in the body.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Xencor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xencor wasn't on the list.
While Xencor currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.